Significance of nuclear hTra2-beta1 expression in cervical cancer

References

• Black DL. Protein diversity from alternative splicing: a challenge for bioinformatics and post.genome biology. Cell 2000; 103: 367–70
   PubMed Web of Science ®Google Scholar
• Blencowe BJ. Alternative splicing: new insights from global analyses. Cell 2006; 126: 37–47
   PubMed Web of Science ®Google Scholar
• Roberts GC, Smith CW. Alternative splicing: combinatorial output from the genome. Curr Opin Chem Biol 2002; 6: 375–83
   PubMed Web of Science ®Google Scholar
• Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007; 8: 349–57
   PubMed Web of Science ®Google Scholar
• Skotheim RI, Nees M. Alternative splicing in cancer: noise, functional, or systematic. Int J Biochem Cell Biol 2007; 39: 1432–49
   PubMed Web of Science ®Google Scholar
• Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004; 64: 7647–54
   PubMed Web of Science ®Google Scholar
• Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev 2003; 17: 419–37
   PubMed Web of Science ®Google Scholar
• Fischer DC, Noack K, Runnebaum IB, Watermann DO, Kieback DG, Stamm S, et al. Expression of splicing factors in human ovarian cancer. Oncol Rep 2004; 11: 1085–90
   PubMed Web of Science ®Google Scholar
• Stoilov P, Meshorer E, Gencheva M, Glick D, Soreq H, Stamm S. Defects in pre-mRNA processing as causes of and predisposition to diseases. DNA Cell Biol 2002; 21: 803–18
   PubMed Web of Science ®Google Scholar
• Aigner A, Juhl H, Malerczyk C, Tkybusch A, Benz CC, Czubayko F. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene 2001; 20: 2101–11
   PubMed Web of Science ®Google Scholar
• Ge K, Minhas F, Duhadaway J, Mao NC, Wilson D, Buccafusca R, et al. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int J Cancer 2000; 86: 155–61
   PubMed Web of Science ®Google Scholar
• Lukas J, Gao DQ, Keshmeshian M, Wen WH, Tsao-Wei D, Rosenberg S, et al. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 2001; 61: 3212–9
   PubMed Web of Science ®Google Scholar
• Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S, et al. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res 2002; 8: 2253–9
   PubMed Web of Science ®Google Scholar
• Wang L, Duke L, Zhang PS, Arlinghaus RB, Symmans WF, Sahin A, et al. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res 2003; 63: 4724–30
   PubMed Web of Science ®Google Scholar
• Daoud R, Mies G, Smialowska A, Olah L, Hossmann KA, Stamm S. Ischemia induces a translocation of the splicing factor tra2-beta 1 and changes alternative splicing patterns in the brain. J Neurosci 2002; 22: 5889–99
   PubMed Web of Science ®Google Scholar
• Watermann DO, Tang Y, Zur Hausen A, Jager M, Stamm S, Stickeler E. Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. Cancer Res 2006; 66: 4774–80
   PubMed Web of Science ®Google Scholar
• Erlandsson F, Martinsson-Ahlzen HS, Wallin KL, Hellstrom AC, Andersson S, Zetterberg A. Parallel cyclin E and cyclin A expression in neoplastic lesions of the uterine cervix. Br J Cancer 2006; 94: 1045–50
   PubMed Web of Science ®Google Scholar
• Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990; 38: 352–7
   PubMed Web of Science ®Google Scholar
• Daoud RDPBM, Siedler F, Hubener M, Stamm S. Activity-dependent regulation of alternative splicing patterns in the rat brain. Eur J Neurosci 1999; 11: 788–802
   PubMed Web of Science ®Google Scholar
• Schaal TD, Maniatis T. Multiple distinct splicing enhancers in the protein-coding sequences of a constitutively spliced pre-mRNA. Mol Cell Biol 1999; 19: 261–73
   PubMed Web of Science ®Google Scholar
• Hopkins MP, Morley GW. Stage IB squamous cell cancer of the cervix: clinicopathologic features related to survival. Am J Obstet Gynecol 1991; 164: 1520–7
   PubMed Web of Science ®Google Scholar
• Morice P, Piovesan P, Rey A, Atallah D, Haie-Meder C, Pautier P, et al. Prognostic value of lymphovascular space invasion determined with hematoxylin-eosin staining in early stage cervical carcinoma: results of a multivariate analysis. Ann Oncol 2003; 14: 1511–7
   PubMed Web of Science ®Google Scholar
• Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005; 16: 481–8
   PubMed Web of Science ®Google Scholar
• Brenner H, Hakulinen T. Long-term cancer patient survival achieved by the end of the 20th century: most up-to-date estimates from the nationwide Finnish cancer registry. Br J Cancer 2001; 85: 367–71
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108
   PubMed Web of Science ®Google Scholar
• Stickeler E, Fraser SD, Honig A, Chen AL, Berget SM, Cooper TA. The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J 2001; 20: 3821–30
   PubMed Web of Science ®Google Scholar
• Mozzetti S, Ferrandina G, Marone M, D'Ingiullo F, Fruscella E, De Pasqua A, et al. Expression of bcl-2, bax-xL, and bcl-xS in endometrial and cervical tissues. Cancer Detect Prev 2000; 24: 536–41
   PubMedGoogle Scholar